13. Charles Rodolphe Brupbacher Symposium, 2017


Dienstag, 31. Januar 2017
19:00 - 20:00 Charles Rodolphe Brupbacher Öffentlicher Vortrag
Reinhard Dummer: Ist Hautkrebs heilbar?
Universität Zürich Zentrum, Rämistrasse 71, G 201 (Aula)

Das folgende wissenschaftliche Symposium findet statt an der
ETH Eidgenössische Technische Hochschule, Rämistrasse 101, Audi Max (HG F 30)

Mittwoch, 1. Februar 2017
12:00 - 13:30 Anmeldung und Sandwich Lunch
13:30 - 15:00 Cancer Genomics

Chair: Holger Moch, Zürich
Richard Houlston: Polygenic susceptiblity to colorectal cancer - mechanism and impact
Jussi Taipale: Systems biology of cancer
Charles Swanton: Cancer chromosomal instability, diversity and evolution: TRACERx

15:00 - 15:30 Kaffeepause
15:30 - 17:30 Cancer Signalling and Targeted Therapy

Chair: Nancy Hynes, Basel
Myles Brown: Hacking the hormone code in cancer
Yibin Kang: Stromal niches in bone that mediate the seeding, progression and treatment resistance of metastatic breast cancer
Lew Cantley: PI 3-kinease and cancer metabolism
Gerard Evan: How and why Ras and Myc cooperate

17:45 - 21:30 Posters, Bier und Brezeln (für alle Teilnehmer) 

Donnerstag, 2. Februar 2017

08:00 - 08:30 Anmeldung und Kaffee
08:30 - 10:00 Genomic Instability

Chair: Lauri Aaltonen, Helsinki
Simon Boulton: Mechanism and regulation of DNA-Protein crosslink repair by the DNA-dependent metalloprotease SPRTN
David Pellman: Rapid Evolution of the cancer karyotype
Angelika Amon: Aneuploidy and cancer - a complicated relationship

10:00 - 10:30 Kaffeepause
10:30 - 12:00 Cancer Epigenetics

Chair: Josef Jiricny, Zürich
Adrian Bird:  Genetic determinants of the epigenome in development and cancer
Maarten van Lohuizen: Context-dependent roles of polycomb repressors in cancer and development
Margaret Goodell: DNMT3A in hematopoietic stem cells, cancer and aging

12:00 - 13:30 Lunch und Kaffee
13:30 - 15:00 Cancer Stem Cells

Chair: Markus G. Manz, Zürich
Kornelia Polyak: Heterogeneity in breast cancer
Benjamin Ebert: Clinical and biological consequences of clonal hematopoiesis
Yusuf Hannun: Contributions of extrinsic factors to cancer

15:00 - 15:30 Kaffeepause
15:30 - 17:00 Tumour Microenvironment, Tumour Immunity

Chair: Alexander Markham, Leeds
Miriam Merad: Contribution of myeloid cells to tumour outcome
Guido Kroemer: Cell death in pathophysiology: inexorable, avoidable or desirable
Laurence Zitvogel: The unsuspected impact of the gut microbiota on cancer immunosurveillance

17:15 - 18:45 Preisverleihung
Charles Rodolphe Brupbacher Prize for Cancer Research 2017
Öffentliche Veranstaltung
19:00 - 19:30 Apéro

Freitag, 3. Februar 2017

08:00 - 08:30 Kaffee
08:30 - 10:00 Breakthrough in Cancer Therapy

Chair: Miriam Mead, New York
Michael Hallek: Towards control of chronic lymphocytic leukemia
Jedd Wolchok: Combination checkpoint Blockade: combinations and mechanisms
Mark O'Connor: Development of olaparib: the first cancer therapy based on a targeted DNA damage response Inhibitor

10:00 - 10:30 Kaffeepause
10:30 - 11:30 Breakthroughs in Cancer Biology

Chair: Markus G. Manz, Zürich
Alberto Bardelli: Cancer Evolution as a therapeutic target
David Lane: Drug discovery in the p53 pathway

11:30 - 12:00 Preisverleihung Young Investigator Award
(Nancy Hynes und Josef Jiricny)
Öffentliche Veranstaltung
12:15 Ende des Veranstaltung